Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04714866
Other study ID # UI-HAM
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 11, 2018
Est. completion date June 10, 2023

Study information

Verified date January 2022
Source University of Iceland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Drug treatment is often the first and only line of treatment available for ADHD. However, some do not benefit from medication. The importance of psychotherapy is becoming more widely accepted. In this study a group of university students diagnosed with ADHD will be offered cognitive behaviour therapy (CBT) in groups. The treatment will be provided by a Clinical Nurse Specialist in psychiatric nursing (CNS), in cooperation with school counsellors at the University of Iceland and the Reykjavík University. Brief CBT treatment will be offered, i.e. six group sessions, once a week over a period of six weeks. Little is known about the effects of CBT for adults diagnosed with ADHD. The study could provide knowledge about the effects of CBT on depression, anxiety and ADHD, and on attitudes, for individuals with ADHD. The resulting knowledge might lead to improved well-being and increased quality of life.


Description:

A treatment manual for adults with ADHD was written based on the CBT model described in Young and Bramham's Handbook on ADHD in Adults (2007), Greenberger and Padesky's Mind Over Mood (2016) and Honos-Webb's The Gift of Adult ADD (2008). Emphasis will be on collaboration, incentive, group interaction and therapy rather than didactic instruction. The manual-based group treatment will be conducted in six sessions. An web page was developed in collaboration with the Faculty of Electrical and Computer Engineering at the University of Iceland containing homework and coping skills assignments to support the participants during therapy. A pilot study has been conducted where adults (n= 5) previously diagnosed with ADHD was offered group CBT in six sessions. The usefulness and benefits of the manual and the App will be evaluated by using questionnaires. Participants was also asked about the group format. The manual and the App will be further developed in light of the pilot study's results. University students with ADHD (n= ........) previously diagnosed by a psychiatrist or a psychologist, will be offered group CBT in six sessions. The study will be introduced to the university students by the school counsellors at the University of Iceland and Reykjavik University. The school counsellors will contact the students and offer them to take part in the therapy. Participants will be randomized into two groups: a waiting list group and a therapy group. The waiting list group will subsequently be offered treatment after a wait of approximately six months. The therapy will be provided by a CNS. CBT sessions will take place once a week over a period of six weeks. Assessments will be conducted before the intervention (baseline), at end of treatment, and at six-month follow-up. In addition, half of the participants will be placed on a waiting list, and will be assessed at the same time as the intervention group (baseline) and again six weeks later, and again six month after that, and will serve as a waiting list comparison group. They will subsequently be offered the treatment intervention and will be included in the intervention group.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 65
Est. completion date June 10, 2023
Est. primary completion date March 5, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: University students who have previously been diagnosed with ADHD, and are fluent in Icelandic. Students with co-morbid disorders such as dyslexia, anxiety or depression will be included. Students currently receiving other psychological or medical treatment will be included. Exclusion Criteria: Students with psychotic disorders, autism spectrum disorders or drug dependence will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Cognitive behavioral therapy for ADHD
CBT is a time-limited and structured approach that influences change in thoughts, feelings and behavior, leading to symptom changes.

Locations

Country Name City State
Iceland University of Iceland Reykjavik Sæmundargata 2

Sponsors (1)

Lead Sponsor Collaborator
University of Iceland

Country where clinical trial is conducted

Iceland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Beck´s Depression Inventory II The inventory includes 21 items that measure depression and well-being during the past two weeks. Options range from 0-3 in each item. The scores can range between 0 and 63. a = 0.89 - 0.94 T1 (at baseline)
Primary Beck´s Depression Inventory II The inventory includes 21 items that measure depression and well-being during the past two weeks. Options range from 0-3 in each item. The scores can range between 0 and 63. a = 0.89 - 0.94 T2 (post-treatment after 6 weeks)
Primary Beck´s Depression Inventory II The inventory includes 21 items that measure depression and well-being during the past two weeks. Options range from 0-3 in each item. The scores can range between 0 and 63. a = 0.89 - 0.94 T3 (follow-up 4-6 months post treatment)
Primary Sense of coherence A. Antonovsky, The inventory includes 29- items with three components; Comprehensibility, manageability and meaningfulness. The items are measured on a 7-point scale. Cronbach´s alpha 0.70-0.95 T1 (at baseline)
Primary Sense of coherence A. Antonovsky, The inventory includes 29- items with three components; Comprehensibility, manageability and meaningfulness. The items are measured on a 7-point scale. Cronbach´s alpha 0.70-0.95 T2 (post-treatment after 6 weeks)
Primary Sense of coherence A. Antonovsky, The inventory includes 29- items with three components; Comprehensibility, manageability and meaningfulness. The items are measured on a 7-point scale. Cronbach´s alpha 0.70-0.95 T3 (follow-up 4-6 months post treatment)
Primary Well-being Dupuy, the questionnaire measures well-being and to how they feel about their inner personal state. The inventory includes 18 items that include negative and positive questions with six components; anxiety, depression, general health, positive well-being, self-control and vitality. Cronbac´s alpha 0.91-0.94 T1 (at baseline)
Primary Well-being Dupuy, the questionnaire measures well-being and to how they feel about their inner personal state. The inventory includes 18 items that include negative and positive questions with six components; anxiety, depression, general health, positive well-being, self-control and vitality. Cronbac´s alpha 0.91-0.94 T2 (post-treatment after 6 weeks)
Primary Well-being Dupuy, the questionnaire measures well-being and to how they feel about their inner personal state. The inventory includes 18 items that include negative and positive questions with six components; anxiety, depression, general health, positive well-being, self-control and vitality. Cronbac´s alpha 0.91-0.94 T3 (follow-up 4-6 months post treatment)
Primary Barkley Adult ADHD rating Scale The questionnaire includes 18- items that are based on DSM-IV criteria for ADHD and is evaluated on a 4-point Likert scale. Cronbach's alpha 0.91-0.93 in the Icelandic version T1 (at baseline)
Primary Barkley Adult ADHD rating Scale The questionnaire includes 18- items that are based on DSM-IV criteria for ADHD and is evaluated on a 4-point Likert scale. Cronbach's alpha 0.91-0.93 in the Icelandic version T2 (post-treatment after 6 weeks)
Primary Barkley Adult ADHD rating Scale The questionnaire includes 18- items that are based on DSM-IV criteria for ADHD and is evaluated on a 4-point Likert scale. Cronbach's alpha 0.91-0.93 in the Icelandic version T3 (follow-up 4-6 months post treatment)
Primary Rosenberg Self-Esteem Scale The scale is a 10-item scale that measures global self-worth using a 4-point Likert scale. Cronbach's alpha 0.87-0.93 T1 (at baseline)
Primary Rosenberg Self-Esteem Scale The scale is a 10-item scale that measures global self-worth using a 4-point Likert scale. Cronbach's alpha 0.87-0.93 T2 (post-treatment after 6 weeks)
Primary Rosenberg Self-Esteem Scale The scale is a 10-item scale that measures global self-worth using a 4-point Likert scale. Cronbach's alpha 0.87-0.93 T3 (follow-up 4-6 months post treatment)
Primary SCL-90 Anxiety subscale The questionnaire includes 10 items related to anxiety symptoms that are evaluated on a 5-point Likert scale. Cronbach's alpha 0.90 T1 (at baseline)
Primary SCL-90 Anxiety subscale The questionnaire includes 10 items related to anxiety symptoms that are evaluated on a 5-point Likert scale. Cronbach's alpha 0.90 T2 (post-treatment after 6 weeks)
Primary SCL-90 Anxiety subscale The questionnaire includes 10 items related to anxiety symptoms that are evaluated on a 5-point Likert scale. Cronbach's alpha 0.90 T3 (follow-up 4-6 months post treatment)
Primary Automatic Thoughts Questionnaire The scale includes 30-item self-statements that measures the frequency of automatic negative thoughts. Thoughts are evaluated on a 5-point scale, how frequent the thoughts are. Chroma's alpha=0.96 T1 (at baseline)
Primary Automatic Thoughts Questionnaire The scale includes 30-item self-statements that measures the frequency of automatic negative thoughts. Thoughts are evaluated on a 5-point scale, how frequent the thoughts are. Chroma's alpha=0.96 T2 (post-treatment after 6 weeks)
Primary Automatic Thoughts Questionnaire The scale includes 30-item self-statements that measures the frequency of automatic negative thoughts. Thoughts are evaluated on a 5-point scale, how frequent the thoughts are. Chroma's alpha=0.96 T3 (follow-up 4-6 months post treatment)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06388694 - Pharmacist Management of Attention Deficit Hyperactivity Disorder Medication Refill Requests N/A
Completed NCT05077722 - Monitoring of Sleep and Behavior of Children 3-7 Years Old Receiving Parent-Child Interaction Therapy With the Help of Artificial Intelligence N/A
Recruiting NCT05924594 - Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301 Phase 3
Active, not recruiting NCT05286762 - Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301 Phase 3
Recruiting NCT06194162 - Weighted Blankets for Sleep Disturbance Among Children With ADHD N/A